Day Two - Informative Clinical Trials

It goes without saying that bigger and more robust datasets provide more informative and reliable insights on the performance of your therapeutics.

Tackling an array of topics critical to reaching your clinical goals, join Merck, AstraZeneca, Regeneron and more to discuss:

  • Advancing clinical studies post-COVID and preparing your trials and teams for unexpected crises
  • How leading industry members are drawing on recent months to rebuild and strategize following lessons from the COVID outbreak
  • Building data-rich clinical trials to inform decision making and expedite pipeline progression
  • Innovative technologies to inform your strategy

And much more!

Key Speakers Include:

Kristina McGuire

Senior Director

Regeneron

Roman Yelensky

Chief Technology Officer

Gritstone Oncology

Vasiliki Pelekanou

Clinical Translational Medical Lead & Oncology

Sanofi

Day Two

WEDNESDAY SEPTEMBER 30, 2020
10.00AM – 3.30 EDT | 7.00AM – 12.30 PDT

9.00 | 6.00 Speed Networking

Synopsis

Grab a quick coffee from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!

9.30 | 6.30 Chair’s Opening Remarks

9.40 | 6.40 Keynote Presentation: Neoantigen Targeted Cancer Immunotherapy in the Clinic

10.00 | 7.00 Taking stock of comprehensive liquid biopsy – where now for patients?

  • Daniel Simon Senior Vice President, BioPharma Business Development, Guardant Health

Synopsis

  • The case for comprehensive genomic profiling is only getting stronger
  • Leveraging FDA approval to improve availability and accessibility
  • Helping patients across the continuum of care

10.20 | 7.20 Live Audience Q+A

  • Roman Yelensky Chief Technology Officer, Gritstone Oncology
  • Daniel Simon Senior Vice President, BioPharma Business Development, Guardant Health

10.40 | 7.40 Speed Networking

Synopsis

Grab a bite to eat from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!

Personalized Medicine in a Post-COVID World

11.40 | 8.40 Impact & Successful Planning for Oncology Clinical Trials Biomarkers in the Era of COVID-19 Crisis: The Sanofi Experience

12.00| 9.00 High Resolution Analysis of Antibody Epitope Repertoire Dynamics in COVID – A Path Towards Understanding Individual Responses And Personalized Disease Assessment

Synopsis

  • Antibody responses to both SARS-CoV-2 and the human proteome play an important role in the course and resolution of COVID disease
  • These responses are dynamic and can differ dramatically from individual to individual
  • Here, we describe our Serum Epitope Repertoire Analysis (SERA) platform and how it has been applied to better understand longitudinal antibody responses to specific epitopes in both the SARS-CoV-2 and human proteomes with high resolutio

12.20 | 9.20 Live Audience Q+A

12.40 | 9.40 Roundtable Discussions

Capture

Clinical Strategy for Biomarker-Driven Trials

1.40 | 10.40 ctDNA in Clinical Trial Design

  • Darren Hodgson Global Project Leader & Head of Strategy, Translational Medicine, AstraZeneca

2.00 | 11.00 Developing & Deploying a Robust, Global Service & Solution Platform to Improve the Quality of Multi-National Registrational Trials

  • Karina Kulangara R&D Director, Companion Diagnostics (CDx), Agilent Technologies
  • Mark Roberts Senior Director, Diagnostics Development, Covance

Synopsis

• What are the challenges of developing and deploying a robust platform
across a global network?
• Discuss best-in-class services & solutions for the successful global rollout
of clinical trials

2.20 11.20 Antibody and protein driven product development to support clinical trial and diagnostic programmes through partnership, from discovery to the clinic in liquid biopsy applications

2.40 | 11.20 Patient Selection & Stratification from Early to Late Stage Development: Cost, Risk & Quality Considerations

3.00 | 12.00 Live Audience Q+A

  • Darren Hodgson Global Project Leader & Head of Strategy, Translational Medicine, AstraZeneca
  • Karina Kulangara R&D Director, Companion Diagnostics (CDx), Agilent Technologies
  • Mark Roberts Senior Director, Diagnostics Development, Covance

3.20 | 12.20 Live Audience Q&A

3.40 | 12.40 Speed Networking

Synopsis

Grab a quick coffee from the comfort of your own kitchen and jump into a another networking session.

4.00 | 1.00 Challenges of getting Trial/Study approval and NGS CDx commercial launch in China

  • Tom Li Head of US Biopharma BD, Burning Rock Dx
  • Dan Liu Regulatory Affairs Manager, Burning Rock Dx (Video Contribution)

R&D Informatics: Driving Biomarker Insight

4.15 | 1.15 Data, Data Everywhere and Not Enough Time to Think: Deploying a Bayesian Approach to Identify Causality in OMICS Data for Population Health & Precision Medicine

  • Michael Kiebish Chief Precision Medicine Officer & Vice President, Systems Medicine, BERG Health

4.45 | 1.45 Live Audience Q+A

  • Michael Kiebish Chief Precision Medicine Officer & Vice President, Systems Medicine, BERG Health
  • Tom Li Head of US Biopharma BD, Burning Rock Dx

5.05 | 2.05 Chair’s Closing Remarks & End of Day Two